These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 22539458)

  • 1. Hepatic lipase activity is increased in non-alcoholic fatty liver disease beyond insulin resistance.
    Miksztowicz V; Lucero D; Zago V; Cacciagiú L; Lopez G; Gonzalez Ballerga E; Sordá J; Fassio E; Schreier L; Berg G
    Diabetes Metab Res Rev; 2012 Sep; 28(6):535-41. PubMed ID: 22539458
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatic Steatosis and Insulin Resistance, But Not Steatohepatitis, Promote Atherogenic Dyslipidemia in NAFLD.
    Bril F; Sninsky JJ; Baca AM; Superko HR; Portillo Sanchez P; Biernacki D; Maximos M; Lomonaco R; Orsak B; Suman A; Weber MH; McPhaul MJ; Cusi K
    J Clin Endocrinol Metab; 2016 Feb; 101(2):644-52. PubMed ID: 26672634
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Post-load insulin resistance is an independent predictor of hepatic fibrosis in virus C chronic hepatitis and in non-alcoholic fatty liver disease.
    Svegliati-Baroni G; Bugianesi E; Bouserhal T; Marini F; Ridolfi F; Tarsetti F; Ancarani F; Petrelli E; Peruzzi E; Lo Cascio M; Rizzetto M; Marchesini G; Benedetti A
    Gut; 2007 Sep; 56(9):1296-301. PubMed ID: 17392334
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Methionine restriction prevents the progression of hepatic steatosis in leptin-deficient obese mice.
    Malloy VL; Perrone CE; Mattocks DA; Ables GP; Caliendo NS; Orentreich DS; Orentreich N
    Metabolism; 2013 Nov; 62(11):1651-61. PubMed ID: 23928105
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma adiponectin in nonalcoholic fatty liver is related to hepatic insulin resistance and hepatic fat content, not to liver disease severity.
    Bugianesi E; Pagotto U; Manini R; Vanni E; Gastaldelli A; de Iasio R; Gentilcore E; Natale S; Cassader M; Rizzetto M; Pasquali R; Marchesini G
    J Clin Endocrinol Metab; 2005 Jun; 90(6):3498-504. PubMed ID: 15797948
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum adipokine levels predictive of liver injury in non-alcoholic fatty liver disease.
    Lemoine M; Ratziu V; Kim M; Maachi M; Wendum D; Paye F; Bastard JP; Poupon R; Housset C; Capeau J; Serfaty L
    Liver Int; 2009 Oct; 29(9):1431-8. PubMed ID: 19422483
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatic fatty acid translocase CD36 upregulation is associated with insulin resistance, hyperinsulinaemia and increased steatosis in non-alcoholic steatohepatitis and chronic hepatitis C.
    Miquilena-Colina ME; Lima-Cabello E; Sánchez-Campos S; García-Mediavilla MV; Fernández-Bermejo M; Lozano-Rodríguez T; Vargas-Castrillón J; Buqué X; Ochoa B; Aspichueta P; González-Gallego J; García-Monzón C
    Gut; 2011 Oct; 60(10):1394-402. PubMed ID: 21270117
    [TBL] [Abstract][Full Text] [Related]  

  • 8. De novo hepatic steatosis drives atherogenic risk in liver transplantation recipients.
    Idowu MO; Chhatrala R; Siddiqui MB; Driscoll C; Stravitz RT; Sanyal AJ; Bhati C; Sargeant C; Luketic VA; Sterling RK; Contos M; Matherly S; Puri P; Siddiqui MS
    Liver Transpl; 2015 Nov; 21(11):1395-402. PubMed ID: 26228654
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nonalcoholic steatohepatitis versus steatosis: adipose tissue insulin resistance and dysfunctional response to fat ingestion predict liver injury and altered glucose and lipoprotein metabolism.
    Musso G; Cassader M; De Michieli F; Rosina F; Orlandi F; Gambino R
    Hepatology; 2012 Sep; 56(3):933-42. PubMed ID: 22684858
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lipoprotein alterations in hemodialysis: differences between diabetic and nondiabetic patients.
    González AI; Schreier L; Elbert A; Berg G; Beresan H; López G; Wikinski R
    Metabolism; 2003 Jan; 52(1):116-21. PubMed ID: 12524671
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fibrosis in genotype 3 chronic hepatitis C and nonalcoholic fatty liver disease: Role of insulin resistance and hepatic steatosis.
    Bugianesi E; Marchesini G; Gentilcore E; Cua IH; Vanni E; Rizzetto M; George J
    Hepatology; 2006 Dec; 44(6):1648-55. PubMed ID: 17133473
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Whole-body substrate metabolism is associated with disease severity in patients with non-alcoholic fatty liver disease.
    Croci I; Byrne NM; Choquette S; Hills AP; Chachay VS; Clouston AD; O'Moore-Sullivan TM; Macdonald GA; Prins JB; Hickman IJ
    Gut; 2013 Nov; 62(11):1625-33. PubMed ID: 23077135
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Associations between plasma adiponectin concentrations and liver histology in patients with nonalcoholic fatty liver disease.
    Targher G; Bertolini L; Rodella S; Zoppini G; Scala L; Zenari L; Falezza G
    Clin Endocrinol (Oxf); 2006 Jun; 64(6):679-83. PubMed ID: 16712671
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The association of the steatosis severity, NAFLD fibrosis score and FIB-4 index with atherogenic dyslipidaemia in adult patients with NAFLD: A cross-sectional study.
    Tutunchi H; Naeini F; Ebrahimi-Mameghani M; Mobasseri M; Naghshi S; Ostadrahimi A
    Int J Clin Pract; 2021 Jun; 75(6):e14131. PubMed ID: 33683797
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Polymorphism in microsomal triglyceride transfer protein: a link between liver disease and atherogenic postprandial lipid profile in NASH?
    Gambino R; Cassader M; Pagano G; Durazzo M; Musso G
    Hepatology; 2007 May; 45(5):1097-107. PubMed ID: 17464986
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Mediterranean diet improves hepatic steatosis and insulin sensitivity in individuals with non-alcoholic fatty liver disease.
    Ryan MC; Itsiopoulos C; Thodis T; Ward G; Trost N; Hofferberth S; O'Dea K; Desmond PV; Johnson NA; Wilson AM
    J Hepatol; 2013 Jul; 59(1):138-43. PubMed ID: 23485520
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The G-250A polymorphism in the hepatic lipase gene promoter is associated with changes in hepatic lipase activity and LDL cholesterol: The KANWU Study.
    Lindi V; Schwab U; Louheranta A; Vessby B; Hermansen K; Tapsell L; Riccardi G; Rivellese AA; Laakso M; Uusitupa MI;
    Nutr Metab Cardiovasc Dis; 2008 Feb; 18(2):88-95. PubMed ID: 17327141
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relation of hepatic steatosis to atherogenic dyslipidemia.
    Makadia SS; Blaha M; Keenan T; Ndumele C; Jones S; DeFilippis A; Martin S; Kohli P; Conceicao R; Carvalho J; Nasir K; Blumenthal R; Santos RD
    Am J Cardiol; 2013 Nov; 112(10):1599-604. PubMed ID: 24012029
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of hepatic steatosis (fatty liver) on severity and composition of dyslipidemia in type 2 diabetes.
    Toledo FG; Sniderman AD; Kelley DE
    Diabetes Care; 2006 Aug; 29(8):1845-50. PubMed ID: 16873790
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low serum adiponectin levels are predictive of advanced hepatic fibrosis in patients with NAFLD.
    Savvidou S; Hytiroglou P; Orfanou-Koumerkeridou H; Panderis A; Frantzoulis P; Goulis J
    J Clin Gastroenterol; 2009 Sep; 43(8):765-72. PubMed ID: 19525862
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.